Original

A retrospective study comparing two formulations of valproic acid

G. Gutiérrez-Gutiérrez, J.J. Poza-Aldea, J.J. Tellería, J.F. Martí-Massó [REV NEUROL 2006;42:129-132] PMID: 16475132 DOI: https://doi.org/10.33588/rn.4203.2005351

OPEN ACCESS

Volumen 42 | Number 03 | Nº of views of the article 6.762 | Nº of PDF downloads 758 | Article publication date 01/02/2006

Download PDF Castellano Citation Search in PubMed

Share in:

Go to another issue

ABSTRACT

INTRODUCTION Valproic acid is available in two different presentations, Depakine ^® and Depakine Crono ^®. Equivalences in plasmatic levels, efficacy and adverse effects between these two formulations are not fully established.

AIM To compare plasmatic levels, efficacy and plasmatic levels between Depakine and Depakine Crono.

PATIENTS AND METHODS We studied a retrospective series of 238 patients in treatment with Depakine or Depakine Crono and compared plasmatic levels, efficacy and adverse effects between both formulations.

RESULTS A total of 173 patients had taken one formulation and 54 both. Plasmatic levels were similar in both groups. There were more significantly more patients free of seizures among the Depakine Crono group. Significantly better outcomes were seen with Depakine Crono with respect to secondary effects. Adverse effects are significantly less frequent in men than in women. The higher the dose, the higher the incidence of adverse events.

CONCLUSIONS Depakine Crono seems to obtain similar plasmatic levels, is at least as efficacious and is associated with less adverse events that Depakine. KeywordsDrug toxicity Efficacy Plasma levels Sustained release Valproate Valproic acid CategoriesTécnicas exploratorias

FULL TEXT (solo disponible en lengua castellana / Only available in Spanish)

Acceso directo al último número

Último Podcast

Original

A retrospective study comparing two formulations of valproic acid